Evaxion A/S (EVAX) Stock: Buy, Sell, or Hold?
EVAX - Evaxion A/S American Depositary Share
$3.76
0.05 (1.35%)
▲
5d:
+32.86%
30d:
+15.34%
90d:
+30.1%
WAIT
LOW Confidence
Analysis Updated: Oct 23, 2026 12:00 AM ET
Earnings: Nov 19, 2026
25d
Get Alerted When EVAX Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 MIXED SIGNALS: EVAX shows conflicting indicators. Wait for confirmation before entering.
📊 MIXED SIGNALS: EVAX shows conflicting indicators. Wait for confirmation before entering.
In-depth Analysis How we analyze
Valuation Analysis: EVAX is currently trading at $3.76, which is considered extended relative to its 30-day fair value range of $2.93 to $3.51. From a valuation perspective, the stock is trading at a discount (Forward PE: -250.7) compared to its historical average (83.6). At these levels, the market is pricing in 0% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, EVAX is showing sideways momentum. Immediate support is located at $2.72, while resistance sits at $4.50.
Market Sentiment: EVAX scores 0/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $12.25 (+225.8%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, EVAX is showing sideways momentum. Immediate support is located at $2.72, while resistance sits at $4.50.
Market Sentiment: EVAX scores 0/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $12.25 (+225.8%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$2.93 -
$3.51
Company Quality Score
32/100
(SELL)
Volume Confirmation
HIGH
Confidence Score
28.6%
All Signals
- BEARISH: Price extended above range (+7.1% above its trading range)
- BEARISH: Weak technical setup (0/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 225.8% below Wall St target ($12.25)
- BULLISH: Market expects only 0% annual growth - appears undervalued
- WARNING: Composite score 32/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$2.93 -
$3.51
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$2.72
Resistance Level
$4.50
Current Trend
Sideways
Technical data as of
Oct 23, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-250.67
Wall Street Target
$12.25
(+225.8%)
Revenue Growth (YoY)
-100.0%
Profit Margin
-115.5%
PE vs Historical
-250.7 vs 83.6
CHEAP
Share & Embed Analysis
Last updated: October 24, 2026 6:01 AM ET
Data refreshes hourly during market hours. Next update: 7:01 AM
Data refreshes hourly during market hours. Next update: 7:01 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is EVAX showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
IONS
Ionis Pharmaceuticals Inc |
STRONG BUY
25 analysts |
$84 | 61 BUY |
|
ACLX
Arcellx Inc |
STRONG BUY
18 analysts |
$113 | 50 HOLD |
|
GPCR
Structure Therapeutics I… |
STRONG BUY
16 analysts |
$106 | 50 HOLD |
|
TSHA
Taysha Gene Therapies Inc |
STRONG BUY
13 analysts |
$13 | 58 HOLD |
|
STOK
Stoke Therapeutics Inc |
STRONG BUY
14 analysts |
$46 | 53 HOLD |